A Rare Histologic Transformation from EGFR-Positive Lung Adenocarcinoma to EGFR-Negative Squamous Cell Carcinoma After EGFR-TKIs Resistance: A Case Report [0.03%]
表皮生长因子受体酪氨酸激酶抑制剂耐药后表皮生长因子受体阳性肺腺癌罕见地向表皮生长因子受体阴性肺鳞癌转化：一例报告
Mengli Qiu,Peiwen Guo,Jieheng Lin et al.
Mengli Qiu et al.
Lung adenocarcinoma (ADC) harboring epidermal growth factor receptor (EGFR) mutations rarely transforms into squamous cell carcinoma (SCC) following resistance to targeted therapy. Here, we present a case of EGFR-positive ADC that transform...
Case Reports
OncoTargets and therapy. 2025 Jul 18:18:803-809. DOI:10.2147/OTT.S513879 2025
The Potential Role and Effective Components of Sanyeqing as the Potential Therapeutic Candidates for IBD and CRC [0.03%]
三清片作为潜在治疗IBD和结直肠癌药物的药效及有效成分研究
Chaoying Chen,Lin Chen,Weifeng Zheng et al.
Chaoying Chen et al.
Inflammatory bowel disease (IBD) is a family of chronic inflammatory diseases such as Crohn's disease (CD) and ulcerative colitis (UC). Among the serious malignancies that can arise from IBD, colorectal cancer is particularly prevalent. Ind...
Biomarker and Prognostic Value of Super-ARMS Detection for EGFR Mutation in Advanced NSCLC [0.03%]
基于超灵敏ARMS技术的EGFR突变检测的生物标志物及预后价值分析
Huicong Liu,Hui Li,Lisha Xiao et al.
Huicong Liu et al.
Background: ctDNA is a non-invasive and convenient method for detecting EGFR mutations in non-small cell lung cancer (NSCLC). However, its sensitivity is lower than that of tissue-based testing. To enhance ctDNA detection...
Survival Outcomes in Lung Cancer Patients Newly Diagnosed Through Brain Metastasis Surgery: Impact of Druggable Mutations and Radiotherapy [0.03%]
肺癌脑转移手术患者的生存结局：可药物治疗突变和放疗的影响
Tzu-I Chuang,Kuo-Hsuan Hsu,Po-Hsin Lee et al.
Tzu-I Chuang et al.
Background: Precocious brain metastasis in lung cancer, diagnosed through surgical resection before primary lung cancer detection, represents a unique clinical scenario with limited research. This study aims to investigat...
Multi‑cohort Validation Based on Disulfidptosis-Related lncRNAs for Predicting Prognosis and Immunotherapy Response of Esophageal Squamous Cell Carcinoma [0.03%]
基于半胱氨酸蛋白酶依赖性细胞死亡相关长链非编码RNA的多队列验证预测食管鳞状细胞癌预后和免疫治疗反应
Zhongquan Yi,Xia Li,Yangyang Li et al.
Zhongquan Yi et al.
Background: Disulfidptosis, a novel pattern of regulatory cell death, provides a valuable opportunity to gain deeper comprehension of tumor pathogenesis and treatment strategies. However, its biological mechanism in esoph...
Lidocaine as a Potential Therapeutic Agent in Colorectal Cancer: A Study of Gene Expression and Prognosis [0.03%]
利多卡因作为结直肠癌治疗药物的潜力：基因表达和预后的研究
Wenyuan Li,Wenjie Gao,Chen Lu et al.
Wenyuan Li et al.
Background: Colorectal cancer (CRC) is a significant contributor to cancer-related mortality globally. Despite the availability of treatments such as surgery, chemotherapy, and radiotherapy, these interventions are often ...
Traditional Chinese Medicine Xiaoai Jiedu Recipe Suppresses the Development of Hepatocellular Carcinoma via Regulating the microRNA-29a/Signal Transducer and Activator of Transcription 3 Axis [Retraction] [0.03%]
抑癌方通过调节microRNA-29a/信号转导及转录激活因子3轴抑制肝细胞癌的发展【撤稿】
[This retracts the article DOI: 10.2147/OTT.S248797.]. © 2025 Dove Medical Press.
Crosstalk Between EGFR and Integrin Affects Invasion and Proliferation of Gastric Cancer Cell Line, SGC7901 [Retraction] [0.03%]
EGFR与整合素的相互作用影响胃癌细胞系SGC7901的侵袭和增殖[撤稿]
[This retracts the article DOI: 10.2147/OTT.S35322.]. © 2025 Dove Medical Press.
Rebecca Lisandrelli,Matthias Winkler,Zlatko Trajanoski et al.
Rebecca Lisandrelli et al.
Purpose: Combination therapies of chemotherapeutic agents and immunotherapy have shown promising results in the treatment of cold tumors. Various chemotherapies trigger immunogenic cell death (ICD) and release of hallmark...
Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma [0.03%]
在泊马西尼和地塞米松联合方案中降低塞利尼克斯剂量可减少副作用而对复发/难治性多发性骨髓瘤具有相当的疗效
Liying Peng,Tiantian Shan,Xinyi Zhou et al.
Liying Peng et al.
Background: As a novel oral Exportin 1 (XPO1) inhibitor, selinexor at 80 or 100 mg has demonstrated efficacy in treating relapsed/refractory multiple myeloma (RRMM), nonetheless, this dosage has shown poor tolerability. ...